Quantcast
Home > Quotes > BCLI

Brainstorm Cell Therapeutics Inc. Common Stock (BCLI) Quote & Summary Data

BCLI 
$3.15
*  
unch
unch
Get BCLI Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading BCLI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
11
Today's High / Low
$ 3.239 / $ 3.13
Share Volume
10,988
50 Day Avg. Daily Volume
52,894
Previous Close
$ 3.15
52 Week High / Low
$ 5.35 / $ 2.88
Market Cap
65,227,797
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.06

Intraday Chart

Shares Traded

Share Volume:
10,988
50 Day Avg. Daily Volume:
52,894

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.41

Trading Range

The current last sale of $3.15 is 9.38% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.239 $ 5.35
 Low: $ 3.13 $ 2.88

Company Description (as filed with the SEC)

Brainstorm Cell Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative Central Nervous System ("CNS") adult stem cell therapies designed to address the significant unmet medical needs of patients with debilitating neurodegenerative diseases. Utilizing our proprietary mesenchymal stem cell platform technology, NurOwn®, Brainstorm is advancing therapies to treat a broad range of neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis ("ALS"), also known as Lou Gehrig's disease), Multiple Sclerosis ("MS"), and Parkinson's disease ("PD"), which currently have limited or no treatment options. 2017 and Recent Highlights · The Company made significant progress in 2017, advancing NurOwn®, our late stage differentiatedmesenchymal stem cell therapy, into a Phase 3 trial for the treatment of ALS.  ... More ...  


Risk Grade

Where does BCLI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.15
Open Date:
Nov. 16, 2018
Close Price:
$ 3.15
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x